Premium
Comedonecrosis is an unfavorable marker in node‐negative invasive breast carcinoma
Author(s) -
Yagata Hiroshi,
Harigaya Kenichi,
Suzuki Masato,
Nagashima Takeshi,
Hashimoto Hideyuki,
Ishii Genichiro,
Miyazaki Masaru,
Nakajima Nobuyuki,
Mikata Atsuo
Publication year - 2003
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1046/j.1440-1827.2003.01514.x
Subject(s) - comedo , carcinoma , immunohistochemistry , pathology , breast carcinoma , medicine , breast cancer , biology , ductal carcinoma , cancer
Breast carcinoma is usually accompanied by an invasive component with an intraductal component, and each component shows different morphological features. We evaluated whether the presence or absence of comedonecrosis is correlated with prognosis and biological features in node‐negative invasive breast carcinoma. Ninety‐four node‐negative breast carcinomas with an intraductal component were classified into two types: comedo type ( n = 36) showing comedonecrosis partly or extensively in the intraductal component, and non‐comedo type ( n = 58) showing either an absence or small foci of necrosis. The Kaplan–Meier method was used to calculate disease‐free survival. Immunohistochemical examination for p53 and HER‐2 was conducted on the comedo ( n = 35) and non‐comedo ( n = 47) type tumor specimens. Disease‐free survival was significantly shorter in the comedo type than in the non‐comedo type ( P = 0.019). The expression of p53 was observed in 16 (45.7%) of the 35 comedo type cases, but only in two (4.3%) of the 47 non‐comedo type cases ( P < 0.0001). HER‐2 overexpression was observed in seven (20.0%) of the 35 comedo type cases, while none of the 47 non‐comedo type cases overexpressed HER‐2 ( P < 0.0001). These results suggest that the presence of comedonecrosis may be predictive of an unfavorable prognosis with aggressive biological behavior in node‐negative invasive breast carcinoma.